Vitrian, a leading end-to-end provider of investment capital and capacity-building services for biomanufacturing, announced that it closed a $50 million investment, with the ability to scale to $65 million, into AmplifyBio’s Manufacturing Enablement Center (AMEC) in New Albany, Ohio as a first step of a more significant commitment to support biomanufacturing in Central Ohio.
AmplifyBio is a leading advanced therapy CRO and CDMO offering a full range of drug development and manufacturing services.
Based in the heart of Central Ohio’s advanced manufacturing corridor, adjacent to Intel’s $20 billion Ohio One semiconductor mega-fab facility and Amgen’s $360 million biomanufacturing plant, the 350,000-square-foot AMEC site is home to AmplifyBio’s multi-modality process development, quality control labs, and GMP manufacturing suites.
KEY QUOTES:
“We are very excited to make our first investment in Ohio and launch a wider partnership with AmplifyBio. We have been impressed by the creativity and progressive thinking of the AmplifyBio team and look forward to further collaborations. The infrastructure investment from state and local government, favorable workforce development environment, and support of important institutional anchors in the Columbus area aligns well with our investment and partnership thesis.”
- Scott Nudelman, Co-Founder and Managing Principal at Vitrian
“We chose to partner with Vitrian based on the alignment of our strategic goals for our manufacturing site, and we are hopeful this is the first of many things we can do together. As we execute our strategy to enable flexible advanced therapy manufacturing and ancillary services, we believe Vitrian will be a great partner.”
- Kelly Ganjei, CEO of AmplifyBio
